Findings from the TRIUMPH-2 clinical trial, released on August 5, 2026, show that retatrutide reduced both body weight and A1C in patients with obesity. The study centered on this patient population and identified the two measures as its principal outcomes. No further details on dosing or trial…
Clinical trial results released on August 5, 2026, show that treatment with retatrutide led to reductions in both body weight and A1C among patients with obesity. The findings come from the TRIUMPH-2 study, a clinical trial centered on this patient population. According to the report, retatrutide produced weight loss and improved A1C levels in the study group.
Weight loss was one of the two key outcomes measured in the TRIUMPH-2 trial. Patients with obesity who were treated with retatrutide experienced decreases in body weight over the course of the study. The reduction in weight was among the principal findings highlighted in the results, and the announcement points to it as a central benefit of treatment.
The second major outcome was A1C, which also declined among patients receiving retatrutide in the TRIUMPH-2 study. The drop in A1C accompanied the weight reduction seen in the same group of patients with obesity. Together, the two measures reflect the trial's core result. Both improved, and both are cited, in the published findings.
The study is identified by the name TRIUMPH-2, and the therapy under investigation is retatrutide. All participants in the trial were patients with obesity. The findings were released on August 5, 2026, and focus on weight and A1C as the main outcomes. The report does not include additional details about dosing, trial size, or duration of treatment.
The TRIUMPH-2 results describe the effect of retatrutide on two important measures in patients with obesity. Weight decreased, and A1C decreased, according to the findings. The announcement, dated August 5, 2026, presents both changes as the principal outcomes of the trial. For researchers and clinicians following obesity treatments, the study provides these results as the central takeaway.
Peptides referenced: Retatrutide.
Related reading: Clinicians Report Mixed Views on Retatrutide Expanded Access, Could GLP-1 Drugs Lower Heart Attack Risk?, Drugmaker to Offer Early Access to Experimental GLP-1 Retatrutide, Everyone Wants 'Reta,' but the Real Retatrutide Isn't Available Yet.